Table of Contents
The GLP-1 patent landscape is no longer a single expiry date — it is a staggered, country-by-country cliff that generic and biosimilar developers must map before they commit a launch. Semaglutide (Novo Nordisk’s Ozempic and Wegovy) and tirzepatide (Eli Lilly’s Mounjaro and Zepbound) anchor a market analysts still size in the tens of billions, and their protection falls apart at wildly different times in the US, Canada, India and Brazil. This page maps who owns what, when each wall comes down, and where the white space actually sits.
Why the GLP-1 Patent Landscape Matters Now
Few therapeutic areas have moved as fast as incretin drugs, and few carry as much money into a patent cliff. Wall Street’s own forecasts have swung by tens of billions: Goldman Sachs now models roughly $95–105 billion in obesity-drug sales by 2030 (revised down from $130 billion), while Morgan Stanley sees the wider market near $190 billion by 2035. Whatever the exact number, the GLP-1 patent landscape is where that revenue is either defended or contested.
The reason the landscape rewards careful reading is that the walls do not fall together. A molecule can be generic in one country and years from competition in another, and a compound-patent expiry rarely clears the way on its own — formulation, device and method-of-use patents sit behind it. For anyone planning entry, the map matters more than the headline date.
Semaglutide: A Patent Cliff That Splits by Country
Semaglutide is the clearest illustration of a fractured cliff. In Canada the main protection expired on January 4, 2026, and in India and Brazil the patent lapsed in March 2026 — yet in the United States patent-term extensions keep semaglutide protected until roughly 2032. Novo Nordisk’s own SEC filings and multiple patent trackers put the core US patent (US 8,129,343) extensions running toward the early 2030s, with additional Orange Book patents reaching later still.
| Drug (maker) | US core-compound exposure | First major cliffs | Notes |
|---|---|---|---|
| Semaglutide — Novo Nordisk | Protected to ~2032 (PTE) | Canada Jan 4, 2026; India & Brazil Mar 2026 | 39 US Orange Book patents, ~19 still active |
| Tirzepatide — Eli Lilly | May 13, 2036 (US 9,474,780) | Formulation/use patents to 2039 | Generic launch effectively delayed to ~2039 |
The commercial effect is already visible. In India at least five domestic drugmakers have launched generic semaglutide at up to 80% below the branded price, with Dr. Reddy’s cleared by regulators and Alkem, Biocon and Sun Pharma close behind. In Canada, Sandoz has signalled discounts of up to 70%. Because India, Canada, China, Brazil and Turkey together hold about 40% of the world’s population, these 2026 expiries reshape access for billions even while the US market stays closed.
Tirzepatide: Protected to 2036 — and 2039 by Formulation
Eli Lilly’s tirzepatide sits several years behind semaglutide on the US calendar. The GIP/GLP-1 co-agonist molecule patent (US 9,474,780) runs to May 13, 2036, but a second layer of formulation and method-of-use patents — including US 11,357,820 — extends practical exclusivity toward June and July 2039. For a developer, that gap between the molecule date and the effective launch date is exactly where a landscape read earns its fee: a design-around that clears 2036 still has to survive the 2039 formulation wall.
The Orange Book Thicket Beyond the Compound Patent
A recurring mistake in reading the GLP-1 patent landscape is treating the compound patent as the finish line. Ozempic alone carries dozens of US drug patents filed between 2018 and 2026 — trackers count 39, of which roughly 19 remain active — spanning solid oral compositions with absorption enhancers, dosing regimens, and the injection pen itself, with dates scattered across 2031, 2034 and 2037.
That layering is deliberate portfolio strategy, and it means a Paragraph IV or biosimilar filer must certify against each listed patent, not one. Novo Nordisk has already settled US ANDA litigation with a series of generics — Alvogen, Sun Pharma, Dr. Reddy’s, Mylan, Zydus and Apotex among them — each settlement fixing an agreed US entry date rather than opening the market outright.
Where the White Space Is
The most valuable output of a landscape study is not the list of what is owned but the read on what is not. Across the current GLP-1 patent landscape, three white-space veins stand out:
- Oral delivery. Peptide bioavailability remains the hard problem; absorption-enhancer and formulation patents are dense but narrow, leaving room for genuinely novel delivery chemistry.
- Next-generation incretins. Triple agonists (GLP-1/GIP/glucagon) and amylin combinations are filing-active but far from saturated, and much of the estate is still in application rather than grant.
- Device design-around. Auto-injector and multi-dose pen patents protect specific mechanisms, not the category — a clean-sheet device can sidestep them.
What the Market Is Actually Worth
Sizing the prize is where discipline matters, because the published estimates disagree by design. For 2030, Goldman Sachs models about $95–105 billion, UBS around $130 billion (cut from over $150 billion), and TD Cowen roughly $139 billion; J.P. Morgan’s broader incretin figure reaches $200 billion. Morgan Stanley pushes the $190 billion case out to 2035. These are analyst forecasts, not facts, and we present them as a range rather than a single number — the point of a landscape study is to stress-test which scenario a specific asset is exposed to.
The World Health Organization’s 2026 addition of GLP-1 receptor agonists to its Essential Medicines List signals where volume, and price pressure, are heading: toward the very markets where the patents have already fallen.
How to Read This Landscape for a Launch Decision
A GLP-1 patent landscape only becomes useful when it is tied to a decision. Our method pairs the cliff calendar above with a freedom-to-operate read for the specific target markets, so a client sees not just when a molecule is exposed but whether their exact product and process can enter without infringing a live formulation, device or method-of-use claim.
That is the difference between a report and a plan. If you are weighing a semaglutide or tirzepatide entry, the landscape sets the timing and the FTO analysis confirms the route.
What You Receive
A GLP-1 landscape engagement from PerspireIP delivers a decision-ready read, not a patent dump:
- Molecule-by-molecule cliff calendar (compound, formulation, device and method-of-use patents) per jurisdiction
- Assignee benchmarking across Novo Nordisk, Eli Lilly and the fast-followers
- Orange Book and equivalent register pull with active-vs-expired status flags
- White-space read on oral delivery, next-generation incretins and device design-arounds
- Launch-timing scenarios tied to each market's expiry and regulatory pathway
Data Sources & References
This analysis draws on primary patent and market data:
- Novo Nordisk Form 20-F (SEC EDGAR) — Issuer disclosure of semaglutide patent protection and US exclusivity to ~2032
- Eli Lilly SEC filings — Tirzepatide (Mounjaro/Zepbound) product and IP disclosures
- mLex — Semaglutide patent expiry global split — Country-by-country expiry timing (Canada Jan 2026, India/Brazil Mar 2026, US 2032)
- FDA — Semaglutide shortage resolution — Feb 21, 2025 resolution and compounding wind-down dates
- Goldman Sachs Research — obesity drug market — 2030 market-size modelling for GLP-1 / anti-obesity drugs
- Morgan Stanley — GLP-1 market to 2035 — $190B by 2035 market forecast
Map Your GLP-1 Entry Window
Get a molecule-by-jurisdiction cliff calendar and a launch-timing read built on primary patent data.
Map Your GLP-1 Entry Window
Related PerspireIP work: freedom-to-operate analysis · GLP-1 biosimilar FTO case study · biotechnology patent intelligence · competitive patent landscape analysis.
Frequently Asked Questions
When does the semaglutide patent expire in the US?
US patent-term extensions keep semaglutide (Ozempic/Wegovy) protected until roughly 2032, even though the patent expired in Canada in January 2026 and in India and Brazil in March 2026. A layer of formulation, oral-dosing and device patents in the Orange Book reaches as far as 2034–2037.
When can generic tirzepatide launch?
Tirzepatide’s molecule patent (US 9,474,780) runs to May 13, 2036, but formulation and method-of-use patents such as US 11,357,820 push effective US exclusivity toward 2039, so a US generic launch is realistically delayed to about 2039 absent a successful challenge.
Why does the GLP-1 patent landscape differ so much by country?
Patent term, term extensions and regulatory classification vary by jurisdiction. Canada and Saudi Arabia treat semaglutide as a chemical drug, while Brazil, India and South Africa classify it as a biologic — which changes both the expiry date and whether a follow-on enters as a generic or a biosimilar.
How big is the GLP-1 market?
Analyst forecasts range widely: roughly $95–139 billion for 2030 (Goldman Sachs, UBS, TD Cowen) and about $190 billion by 2035 (Morgan Stanley). We treat these as a scenario range, not a single figure, when sizing exposure for a specific asset.
What does a GLP-1 landscape study include?
A cliff calendar per molecule and jurisdiction, assignee benchmarking, an Orange Book pull with active/expired flags, a white-space read on oral delivery and next-generation incretins, and launch-timing scenarios tied to a freedom-to-operate analysis for the target markets.